Theranostics pairs a diagnostic imaging isotope with a therapeutic isotope using the same molecular target. For example:
This allows clinicians and developers to:
We specialise in designing and executing these paired studies.
Currently, radiopharmaceuticals are primarily used in oncology, including:
The field is rapidly expanding as new targets, diseases and isotopes become clinically validated.
Nuclear medicine uses radioactive materials for imaging and therapy. In oncology, it enables non‑invasive visualisation of tumour biology and targeted delivery of radiation to cancer cells.
TRPs are also forms of RPT, precision medicines that combine a targeting vector with a radioactive payload. They can be used for diagnosis, therapy, or both (theranostics), depending on the isotope selected.
RLT is a form of RPT where a targeting ligand (small molecule, peptide, antibody, nanobody) is linked to a therapeutic radionuclide such as ¹⁷⁷Lu, ²²⁵Ac, or ²¹²Pb and others. The ligand finds the tumour; the radionuclide delivers the therapeutic effect.
RPT uses targeted radioactive drugs to deliver radiation directly to tumour cells. These agents bind to specific molecular targets, enabling highly selective treatment while sparing healthy tissue.
We work across:
Yes, we offer:
These complement our in vivo imaging and efficacy platforms.
Absolutely. Our radiochemists routinely develop and optimise chelator–linker systems for peptides, antibodies, nanobodies, and small molecules, including stability testing, immunoreactivity, and radiolabelling optimisation.
Yes. We perform preclinical dosimetry using clinical‑standard software aligned with MIRD methodologies and FDA guidance. This includes ex vivo biodistribution time activity curves and longitudinal voxel‑based and organ‑level dose estimation.
Our preclinical imaging suite includes:
These enable biodistribution, PK/PD, efficacy, and dosimetry studies across multiple isotopes.
We are licensed for a broad suite of alpha and beta emitters, including: ²²⁵Ac, ²¹²Pb, ¹⁷⁷Lu, ⁸⁹Zr, ⁶⁸Ga, ¹⁸F, ⁹⁹ᵐTc, ¹¹¹In, 64Cu, 67Cu, 161Tb and others. This supports both diagnostic imaging and therapeutic development.
By integrating radiochemistry, in vivo biology, multimodal imaging, dosimetry, and quantitative image analysis under one roof, we remove the operational friction that slows most RPT programmes. This enables faster study execution, cleaner datasets, and investor‑ready packages aligned with FDA/EMA expectations.
We specialise in diagnostic–therapeutic isotope pairing, such as ⁸⁹Zr → ¹⁷⁷Lu or ²⁰³Pb → ²¹²Pb and ⁶4Cu → ⁶⁷Cu enabling prediction of therapeutic uptake, safety, and efficacy in real time.
Yes, through our strategic partnerships, we provide access to 1,400+ annotated PDX models, enabling highly predictive translational studies.
Absolutely. Our radiochemists specialise in bespoke chelator/linker optimisation, stability testing, immunoreactivity, and radiolabelling of peptides, antibodies, nanobodies, and small molecules.
We are licensed for a broad suite of isotopes including ²²⁵Ac, ²¹²Pb, ¹⁷⁷Lu, ⁸⁹Zr, ⁶⁸Ga, ¹⁸F, ⁹⁹ᵐTc, ⁶⁷Cu, ¹⁶¹Tb and others.
We provide end‑to‑end radiochemistry support, including:
These capabilities ensure that imaging agents and therapeutic candidates are robust, stable, and ready for in vivo evaluation.
We operate a full suite of high‑performance preclinical imaging platforms, including:
We work across a range of translationally relevant models, including:
This breadth enables highly predictive imaging and efficacy studies across oncology and other therapeutic areas.
We bring radiochemistry, in vivo biology, multimodal imaging, dosimetry, and quantitative analysis together in a single, coordinated workflow. We perform everything on‑site, from radiolabelling to imaging to biodistribution and PK/PD modelling, ensuring tight QC, consistent datasets, and faster turnaround. This integration reduces friction between development stages and produces clean, decision‑ready data that supports IND/IMPD submissions, investor milestones, and rapid programme progression.
We support programmes from target validation through IND‑enabling studies, with expertise across:
Our integrated platform enables clients to de‑risk candidate selection, optimise dosing strategies, and generate the translational evidence needed for regulatory progression and investment.
We provide end‑to‑end pre‑clinical translational imaging and radiopharmaceutical development, including:
We provide quantitative image analysis, semi‑automated segmentation, and reproducible PK/PD and dosimetry pipelines, delivering decision‑ready data trusted by pharma and emerging biotechs.
We use clinical‑standard dosimetry platforms aligned with MIRD methodologies, ensuring smooth progression into regulatory submissions.
We support preclinical packages that feed directly into Phase 0 designs and collaborate with clinical partners for translational imaging and early‑human readiness.
Yes, we offer consultative study design, including:
Yes, our study designs, dosimetry workflows, and reporting formats follow FDA guidance, IAEA recommendations, and EMA expectations.
We offer imaging capabilities including:
This ensures a smooth handover from preclinical to clinical imaging, supporting Phase 0, Phase I, and theranostic trial designs.
We provide a complete pre‑clinical RPT development pathway, including:
Our integrated approach accelerates progression from concept to clinic while reducing programme risk.
We design fully bespoke imaging and in vivo studies, including:
We work as an extension of your scientific team, ensuring each study is fit for purpose, translatable, and aligned with your development strategy.
Our integrated workflows reduce hand‑offs, compress timelines, and generate regulatory‑aligned biodistribution, dosimetry, PK/PD, and efficacy datasets in one place. The result: investor‑ready packages that move programmes into the clinic with confidence.
We combine radiochemistry, in vivo biology, multimodal imaging, dosimetry, and quantitative analysis in a single, tightly integrated unit. This eliminates the outsourcing gaps that slow most programmes and delivers cleaner data, faster timelines, and lower development risk.
Our BD and project management teams operate with US‑friendly hours, structured communication, and predictable reporting cycles.
Because we deliver speed, quality, and reliability at a level that outperforms many US providers, with no compromise on regulatory alignment. Our location also avoids the bottlenecks and capacity constraints currently affecting US RPT CROs.
We are structured to support US biotechs and pharma with fast, reliable, high‑quality data. We deliver high‑performance data, predictable timelines, and exceptional reliability, without the bottlenecks common in the US market.
Not currently. We focus on pre‑clinical development, but our workflows are designed to dovetail with GMP partners and CDMOs for seamless progression to clinical supply.
Through strategic partnerships and national initiatives, we support access to key isotopes including ²¹²Pb and ²²⁵Ac, reducing supply chain risk for clients. We have multiple supply agreements across our library of isotopes.
We support everyone from seed‑stage biotechs to global pharma, guiding on data needs and study design as well as providing the data packages needed for fundraising, partnering, and regulatory progression.
Yes, many clients engage us as a strategic extension of their RPT platform, leveraging our integrated capabilities across multiple programmes, assets and modalities.
Yes, our radiochemistry, imaging, and in vivo teams operate in coordinated workflows that support parallel study execution without compromising quality.
Our integrated model and on‑site isotope access allows rapid initiation. Timelines depend on isotope availability, model readiness, and study complexity, but we’re engineered to operate at speed.
Not consistently. We are explicitly aligned with FDA and EMA guidance, giving clients a smoother path to IND.
Yes! Our integrated model reduces outsourcing costs, repeat studies, and delays, delivering better value per dataset.
Some offer elements, but we specialise in diagnostic–therapeutic isotope pairing, surrogate imaging, and regulatory aligned dosimetry.
Few match our combination of PET, SPECT, CT, IVIS, ultrasound, quantitative analysis, and dosimetry in one facility.
Unlike newer entrants, we have licensed facilities, established infrastructure, validated models, and a proven track record – reducing risk for clients.
We don’t outsource radiochemistry, imaging, or in vivo biology. We deliver true in‑house integration, ensuring data consistency and faster turnaround.
We offer the same integrated capabilities but with greater agility, faster initiation, and lower operational friction. We specialise in pre‑clinical RPT, not broad CRO services, meaning deeper focus and higher precision. While some competitors rely heavily on outsourcing, we utilise our full-stack in house capabilities, enabling faster turnaround, tighter QC, and more coherent datasets.
We continually drive innovation at pace, including a broad understanding of the radiobiology alongside the RPT translations and a broad understanding of incorporating combination therapies and small molecules in combination with the RPT.
Ready to bring momentum to your radiopharmaceutical program?
Our experts are here to support your journey from concept to clinic. Contact our team to discuss a tailored solution.
Fill in the form today and speak to us to see how we can help advance your drug discovery project.
